Machina Capital S.A.S. Has $727,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

• Machina Capital S.A.S. significantly decreased its stake in Gilead Sciences, cutting holdings by 62.5% in the first quarter, reducing ownership to 6,484 shares valued at approximately $727,000.
• Several large institutional investors have recently increased their positions in Gilead, with Norges Bank purchasing shares worth about $1.79 billion and FMR LLC expanding its stake by 21.6%.
• Gilead's stock recently saw a 2.7% increase, closing at $116.20, following positive earnings that exceeded analysts' expectations despite a slight revenue decline year-over-year.

Machina Capital S.A.S. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 62.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,484 shares of the biopharmaceutical company's stock after selling 10,826 shares during the period. Machina Capital S.A.S.'s holdings in Gilead Sciences were worth $727,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences during the 1st quarter valued at approximately $25,000. Goodman Advisory Group LLC purchased a new stake in Gilead Sciences in the 1st quarter worth approximately $29,000. Core Alternative Capital raised its position in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 241 shares in the last quarter. IMA Advisory Services Inc. purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at $39,000. Finally, Annis Gardner Whiting Capital Advisors LLC boosted its stake in Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 216 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Price Performance

Gilead Sciences stock traded down $1.90 during midday trading on Monday, reaching $114.30. 2,119,953 shares of the company were exchanged, compared to its average volume of 8,466,501. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The company has a market capitalization of $142.18 billion, a price-to-earnings ratio of 24.07, a P/E/G ratio of 0.73 and a beta of 0.29. The firm's 50-day simple moving average is $109.91 and its 200-day simple moving average is $106.12. Gilead Sciences, Inc. has a 1 year low of $72.43 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company's revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.32) EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of recent analyst reports. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target on the stock. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research report on Friday. Oppenheimer decreased their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Finally, Morgan Stanley lifted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Eight equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $112.36.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the transaction, the insider directly owned 121,152 shares in the company, valued at $13,026,263.04. This represents a 18.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company's stock, valued at approximately $978,880.80. The trade was a 35.92% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,000 shares of company stock valued at $7,844,775. Company insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.